Active ingredient in Ozempic shows early promise for treating alcohol use disorder
A new study from Mental Health Center Copenhagen found that semaglutide, the active ingredient in Ozempic and Wegovy, reduced heavy drinking days by 41% in adults with obesity and alcohol use disorder over six months. Participants received weekly semaglutide injections or a placebo alongside therapy, with the drug group showing greater reductions in alcohol use, cravings, and improved metabolic health. The study, published in The Lancet, is the first randomized controlled trial to evaluate GLP-1 drugs for alcohol use disorder in people actively seeking treatment.
Opening excerpt (first ~120 words) tap to expand
ABC NewsLiveVideoShowsGood Morning AmericaShopGMAInterest Successfully AddedWe'll notify you here with news aboutTurn on desktop notifications for breaking stories about interest? OffOnStream onActive ingredient in Ozempic, Wegovy shows early promise for treating alcohol use disorder among those with obesity: StudySemaglutide cut heavy drinking days by about 41%, the study found.ByDr. Grace HaganApril 30, 2026, 6:45 PM7:30Boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California.Mario Tama/Getty ImagesThe active ingredient found in popular weight-loss drugs used by millions of people may also help reduce alcohol use in those with obesity, a new study finds.Researchers from Mental Health Center Copenhagen in Denmark examined 108 adults with…
Excerpt limited to ~120 words for fair-use compliance. The full article is at ABC News: Top Stories.
Discussion
0 commentsMore from ABC News: Top Stories
